81 related articles for article (PubMed ID: 6436151)
1. Effects of an antiestrogen on subfractions of HDL cholesterol during estrogen replacement therapy.
Ottosson UB; Carlström K; Johansson BG; von Schoultz B
Gynecol Obstet Invest; 1984; 18(3):140-6. PubMed ID: 6436151
[TBL] [Abstract][Full Text] [Related]
2. Oral progesterone and estrogen/progestogen therapy. Effects of natural and synthetic hormones on subfractions of HDL cholesterol and liver proteins.
Ottosson UB
Acta Obstet Gynecol Scand Suppl; 1984; 127():1-37. PubMed ID: 6596830
[TBL] [Abstract][Full Text] [Related]
3. Estrogen induction of liver proteins and high-density lipoprotein cholesterol: comparison between estradiol valerate and ethinyl estradiol.
Ottosson UB; Carlström K; Johansson BG; von Schoultz B
Gynecol Obstet Invest; 1986; 22(4):198-205. PubMed ID: 3817605
[TBL] [Abstract][Full Text] [Related]
4. Estrogen replacement therapy after the menopause. Estrogenicity and metabolic effects.
Helgason S
Acta Obstet Gynecol Scand Suppl; 1982; 107():1-29. PubMed ID: 6282033
[TBL] [Abstract][Full Text] [Related]
5. Effects of conjugated equine estrogen with and without three different progestogens on lipoproteins, high-density lipoprotein subfractions, and apolipoprotein A-I.
Miller VT; Muesing RA; LaRosa JC; Stoy DB; Phillips EA; Stillman RJ
Obstet Gynecol; 1991 Feb; 77(2):235-40. PubMed ID: 1846437
[TBL] [Abstract][Full Text] [Related]
6. Antiestrogenic properties of raloxifene.
Draper MW; Flowers DE; Neild JA; Huster WJ; Zerbe RL
Pharmacology; 1995 Apr; 50(4):209-17. PubMed ID: 7792309
[TBL] [Abstract][Full Text] [Related]
7. Subfractions of high-density lipoprotein cholesterol during estrogen replacement therapy: a comparison between progestogens and natural progesterone.
Ottosson UB; Johansson BG; von Schoultz B
Am J Obstet Gynecol; 1985 Mar; 151(6):746-50. PubMed ID: 3976784
[TBL] [Abstract][Full Text] [Related]
8. Effect of toremifene on estrogen primed vaginal mucosa in postmenopausal women.
Mäenpää J; Söderström KO; Grönroos M; Taina E; Hajba A; Kangas L
J Steroid Biochem; 1990 Jun; 36(3):221-3. PubMed ID: 2142237
[TBL] [Abstract][Full Text] [Related]
9. Relative fatty acid composition of lecithin during postmenopausal replacement therapy--a comparison between ethinyl estradiol and estradiol valerate.
Ottosson UB; Lagrelius A; Rosing U; von Schoultz B
Gynecol Obstet Invest; 1984; 18(6):296-302. PubMed ID: 6519560
[TBL] [Abstract][Full Text] [Related]
10. The relationship of total and free estrogens and sex hormone-binding globulin with lipoproteins in women.
Longcope C; Herbert PN; McKinlay SM; Goldfield SR
J Clin Endocrinol Metab; 1990 Jul; 71(1):67-72. PubMed ID: 2115047
[TBL] [Abstract][Full Text] [Related]
11. Effects of tamoxifen treatment on plasma lipids and lipoprotein lipid composition.
Bagdade JD; Wolter J; Subbaiah PV; Ryan W
J Clin Endocrinol Metab; 1990 Apr; 70(4):1132-5. PubMed ID: 2318936
[TBL] [Abstract][Full Text] [Related]
12. A comparative study of the estrogenic effects of tamoxifen and 17 beta-estradiol in postmenopausal women.
Helgason S; Wilking N; Carlström K; Damber MG; von Schoultz B
J Clin Endocrinol Metab; 1982 Feb; 54(2):404-8. PubMed ID: 6798066
[TBL] [Abstract][Full Text] [Related]
13. Effects of desogestrel and gestodene in low-dose oral contraceptive combinations on lipid and lipoprotein status. A randomized prospective study.
Granata A; Sobbrio GA; D'Arrigo F; Barillari M; Curasì MP; Egitto M; Trimarchi F; Granese D; Pullè C
Acta Eur Fertil; 1990; 21(3):143-6. PubMed ID: 2149913
[TBL] [Abstract][Full Text] [Related]
14. Effect of oestriol, oestradiol valerate and ethinyloestradiol on serum proteins in oestrogen-deficient women.
Bergink EW; Crona N; Dahlgren E; Samsioe G
Maturitas; 1981 Dec; 3(3-4):241-7. PubMed ID: 7199609
[TBL] [Abstract][Full Text] [Related]
15. Antiatherogenic effects of adjuvant antiestrogens: a randomized trial comparing the effects of tamoxifen and toremifene on plasma lipid levels in postmenopausal women with node-positive breast cancer.
Saarto T; Blomqvist C; Ehnholm C; Taskinen MR; Elomaa I
J Clin Oncol; 1996 Feb; 14(2):429-33. PubMed ID: 8636753
[TBL] [Abstract][Full Text] [Related]
16. Effects of progestogen on lipids, lipoproteins and apolipoproteins during transdermal estrogen replacement therapy with and without medroxyprogesterone acetate.
Castelo-Branco C; Casals E; Sanllehy C; Duran M; Fortuny A; Vanrell JA
J Reprod Med; 1996 Nov; 41(11):833-8. PubMed ID: 8951134
[TBL] [Abstract][Full Text] [Related]
17. RU 16117, an orally active estriol-like weak estrogen.
Raynaud JP; Azadian-Boulanger G; Bouton MM; Colin MC; Faure N; Fernand-Proulx L; Gautray JP; Husson JM; Jolivet A; Kelly P
J Steroid Biochem; 1984 Apr; 20(4B):981-93. PubMed ID: 6427528
[TBL] [Abstract][Full Text] [Related]
18. Estrogenic potency of oral replacement therapy estimated by the induction of pregnancy zone protein.
Helgason S; Damber MG; von Schoultz B; Stigbrand T
Acta Obstet Gynecol Scand; 1982; 61(1):75-9. PubMed ID: 6283781
[TBL] [Abstract][Full Text] [Related]
19. Droloxifene, a new antiestrogen. Hormonal influences in postmenopausal breast cancer patients.
Kvinnsland S
Am J Clin Oncol; 1991; 14 Suppl 2():S46-51. PubMed ID: 1962597
[TBL] [Abstract][Full Text] [Related]
20. Serum lipids, lipoproteins, and apolipoproteins during postmenopausal estrogen replacement therapy combined with either 19-nortestosterone derivatives or 17-hydroxyprogesterone derivatives.
Haarbo J; Hassager C; Jensen SB; Riis BJ; Christiansen C
Am J Med; 1991 May; 90(5):584-9. PubMed ID: 1827568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
